Since GLP-1 is cleaved by dipeptidyl peptidase-4 and has a half-life of less than 2 minutes, it is likely that intestinal GLP-1, released after eating, exerts its effect on the brain mainly by interacting with vagus afferent neurons located in the porta hepatis and pylorus
dosing is slowly escalated from lower doses to reduce side effects and improve tolerance
Additional safety considerations include caution in patients with severe gastroparesis, and a potential risk of diabetic retinopathy complications with rapid glucose improvement, particularly with semaglutide
LearnWise Simple and engaging content, makes learning effortless
For Canadian patients considering GLP-1 therapy, access is only the first decision
The condition affects women much more than men